-
Biotech Stock On The Radar: Anavex, A Neurology-Focused Precision Medicine Company
Wednesday, September 25, 2019 - 5:32pm | 7 min readThe European Rett Syndrome Conference gets underway Friday in Finland. Among the presenters: a New York-based micro-cap biotech that has an investigational asset to treat Rett syndrome in its pipeline. Anavex Life Sciences Corp (NASDAQ: AVXL), founded in 2006, is a biotech that focuses...
-
Analysts Positive On Insys Ahead Of 2019 Pipeline Catalysts
Friday, March 8, 2019 - 11:38am | 2 min readInsys Therapeutics Inc (NASDAQ: INSY), which specializes in painkillers and synthetic cannabinoid drugs, reported Thursday after the close with a sharp decline in revenue and a wider-than-expected loss in the fourth quarter. The Analysts Janney analyst Yun Zhong reiterated a Buy...
-
Analysts Laud Sarepta's 'Increasingly Active' Gene Therapy Clinical Development
Thursday, February 28, 2019 - 3:09pm | 3 min readSarepta Therapeutics Inc (NASDAQ: SRPT) reported fourth-quarter results Wednesday alongside positive results for its muscular dystrophy gene therapy candidate. The Analysts Janney analyst Yun Zhong reiterated a Buy rating on Sarepta with a $200 fair value estimate. Cantor Fitzgerald analyst...
-
Janney: Cannabis, Naloxone, Adrenaline The Perfect Mix For Insys
Saturday, January 19, 2019 - 10:36am | 2 min readWith a blooming cannabis portfolio, an EpiPen alternative and a potent solution to opioid overdoses, Insys Therapeutics Inc (NASDAQ: INSY) is claiming space in some of biotech’s hottest segments. Some on the Street see “significant upside potential.” The Rating Janney analyst Yun...
-
Janney, Morgan Stanley Say Sarepta's Gene Therapy Remains On Track
Tuesday, January 8, 2019 - 3:11pm | 2 min readSarepta Therapeutics Inc (NASDAQ: SRPT) shares were under pressure this week following a regulatory update that analysts say may have been misunderstood by the market. Sarepta shares were down 5 percent at the start of the week against a biotech index that was up 3 percent after the...
-
Analyst: Insys To Benefit As FDA Pushes Naloxone Access
Wednesday, December 19, 2018 - 12:07pm | 2 min readAs Insys Therapeutics Inc (NASDAQ: INSY) shifts from opioid therapies to cannabinoids and spray technology, one analyst sees an opportunity to buy in. The Rating Janney analyst Yun Zhong assumed coverage with a Buy rating and cut his price target from $16 to $11. The Thesis Insys forecasted at...
-
Janney Upgrades bluebird bio Ahead Of Sickle Cell Presentation
Monday, November 5, 2018 - 1:09pm | 2 min readShares of bluebird bio Inc. (NASDAQ: BLUE) surged over 13 percent last week as the company announced plans to release abstracts at the American Society of Hematology meeting in December. The Analyst Janney analyst Yun Zhong upgraded bluebird from Neutral to Buy and maintained a $170 price...
-
Janney: Nightstar Therapeutics Has 'Significant Upside Potential' With Retinal Disorder Treatments
Wednesday, August 22, 2018 - 10:21am | 2 min readNightstar Therapeutics PLC (NASDAQ: NITE) leads the market in adeno-associated virus gene therapy for the treatment of inherited retinal disorders, according to a bullish Janney analyst. The Analysts Analyst Yun Zhong initiated coverage of Nightstar with a Buy rating and $34 price...
-
Waters Has Limited Upside Potential To Growth Expectations; Janney Steps to The Sidelines
Tuesday, July 17, 2018 - 12:55pm | 2 min readThere are better alternatives to Waters Corporation (NYSE: WAT) in the life sciences tools sector from the perspective of acceleration in organic growth, according to an analyst at Janney. The Analyst Paul Knight downgraded Waters Corp from Buy to Neutral and lowered his fair value estimate from $...
-
Janney: 4 Reasons Why Selecta Biosciences Is 'Significantly Undervalued'
Wednesday, June 27, 2018 - 12:26pm | 2 min readSelecta Biosciences Inc (NASDAQ: SELB) shares plummeted in November 2017 from the $20 level and have yet to recover. The stock should not only recoup all of its losses, but trade at new all-time highs, according to Janney. The Analyst Janney's Yun Zhong initiated coverage of Selecta...
-
Summit Therapeutics' Upcoming Duchenne Muscular Dystrophy Data 'A Strong Catalyst,' Janney Says In Bullish Initiation
Saturday, May 5, 2018 - 12:55pm | 2 min readSUMMIT THERAPEU/S ADR (NASDAQ: SMMT) is conducting clinical trials for Duchenne muscular dystrophy, or DMD, and clostridium difficile infection, or CDI. The Analyst Janney analyst Yun Zhong initiated coverage of Summit Therapeutics with a Buy rating and $27 fair value estimate. The Thesis...
-
Janney Upgrades American Water Works After Pivotal Acquisition: 'The Upside Potential Outweighs Downside Risk'
Monday, April 16, 2018 - 10:58am | 2 min readAmerican Water Works Company Inc (NYSE: AWK) announced April 11 an agreement to acquire Pivotal Home Solutions, a unit of Southern Co (NYSE: SO), for $365 million in cash. Since the announcement, the stock has shed over 1 percent, while it also trading well off its high for the year. The...
-
Janney: Buy The Dip In Uniqure
Tuesday, March 20, 2018 - 11:39am | 3 min readUniqure NV (NASDAQ: QURE) shares slid 22 percent in two weeks with no fundamental changes, prompting a Janney analyst to recommend buying the dip. The Analyst Janney analyst Yun Zhong reiterated a Buy rating on the shares of Uniqure and increased the fair value estimate from $25 to $30....
-
Janney Says Bluebird's Therapies Are 'Encouraging,' But Stock Is Fairly Valued
Wednesday, March 14, 2018 - 9:53am | 2 min readBluebird bio Inc (NASDAQ: BLUE), a clinical-stage biotechnology company that focuses on therapies for the treatment of severe diseases and cancer, released "highly encouraging" clinical data in late 2017, according to Janney. But that doesn't mean investors should be aggressive buyers...
-
Janney Cites CDM Acquisition In Bullish Stance On USA Compression Partners
Monday, March 5, 2018 - 3:58pm | 2 min readUsa Compression Partners LP (NYSE: USAC) is one of the largest independent provider of compression services in terms of fleet horsepower and the recent acquisition of CDM Resource Management makes the stock attractive, according to Janney. The Analyst Janney's Michael Gyure upgraded Usa...